New York Life Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

New York Life Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.38M	Sell	24,104 -2,661	-10%	-$146K	0.01%	623
2026 Q1	$1.51M	Buy	26,765 +8,608	+47%	+$502K	0.01%	595
2025 Q4	$1.08M	Sell	18,157 -1,626	-8%	-$88.5K	0.01%	593
2025 Q3	$1.07M	Buy	+19,783	New	+$1.13M	0.01%	643
2024 Q4	–	Sell	-4,758	Closed	-$334K	–	825
2024 Q3	$334K	Buy	4,758 +308	+7%	+$25.7K	﹤0.01%	827
2024 Q2	$366K	Buy	+4,450	New	+$370K	﹤0.01%	816

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

New York Life Investment Management's BMRN Position: Q2 2026 in Review

New York Life Investment Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 9.9% in Q2 2026, selling an estimated $146K and leaving 24,104 shares worth $1.38M. The position accounts for 0.01% of the portfolio, ranked #623.

New York Life Investment Management first reported a position in BMRN in Q2 2024 and has held it in 6 quarters since. The position peaked at $1.51M in Q1 2026. 360 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

New York Life Investment Management held 24,104 shares of BioMarin Pharmaceuticals worth $1.38M as of Q2 2026.
New York Life Investment Management sold 2,661 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $146K.
BioMarin Pharmaceuticals made up 0.01% of New York Life Investment Management's portfolio in Q2 2026, its #623 holding.
New York Life Investment Management first reported a position in BioMarin Pharmaceuticals in Q2 2024 and has held it in 6 quarters since.
New York Life Investment Management's BioMarin Pharmaceuticals position peaked at $1.51M in Q1 2026.
360 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on New York Life Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.